反应详情

A solution of 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)aniline (110 mg, 0.22 mmol) in a mixture of dichloromethane (10 mL) and tetrahydrofuran (10 mL) was treated with triethylamine (0.10 mL), followed by triphosgene (100 mg, 0.34 mmol). After the passage of five minutes, 2.0 M methylamine solution in tetrahydrofuran (10 mL) was added. The mixture was concentrated to dryness under reduced pressure. The resultant residue was purified via reverse-phase high performance liquid chromatography using a Phenomenex Prodigy 21 mm×250 mm column, running a gradient elution of 10% acetonitrile/90% of 0.1% aqueous trifluoroacetic acid to 95% acetonitrile. After the concentration of fractions under reduced pressure, 1-methyl-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}phenyl)urea was obtained. MS (ES+): 545.2 (M+H)+

1. concentrationThe mixture was concentrated to dryness under reduced pressure
2. customThe resultant residue was purified via reverse-phase high performance liquid chromatography
3. washa gradient elution of 10% acetonitrile/90% of 0.1% aqueous trifluoroacetic acid to 95% acetonitrile